Next Generation RNA Therapeutics Summit
When:
Monday, May 24, 2021 9:00a -
Thursday, May 26, 2022 4:00p
Monday, May 24, 2021 9:00a -
Thursday, May 26, 2022 4:00p
Where:
Omni Parker House
60 School Street
Boston, Massachusetts 02108
Admission:
$Drug Developer Pricing - Conference + 2 Workshops - On the Door USD 4197.00 Drug Developer Pricing - Conference + 1 Workshop - On the Door USD 3598.00 Drug Developer Pricing - Conference Only - On the Door USD 2999.00 Industry Pricing - Conference + 2 Workshops - On the Door USD 5097.00 Industry Pricing - Conference + 1 Workshop - On the Door USD 4348.00 Industry Pricing - Conference Only - On the Door USD 3599.00 Research Institutes Pricing - Conference + 2 Workshops - On the Door USD 3697.00 Research Institutes Pricing - Conference + 1 Workshop - On the Door USD 3148.00 Research Institutes Pricing - Conference Only - On the Door USD 2599.00
Categories:
Lectures & Conferences
Event website:
https://go.evvnt.com/996084-0?pid=5248
Built with biopharmaceutical industry insights, this in-person conference will delve into novel and emerging RNA therapeutics and vaccines such as self-amplifying mRNA vaccines, circular RNA therapeutics, and tRNA-based gene therapies to the scene for discovery and translation of novel modalities that offer superior targeted delivery, selectivity, durability, and scalability compared to the current generations.
With 20+ pioneering speakers from large pharma, innovative biotech, and KOLs of academia who are shaping the landscape of next-generation RNA therapeutics for the scientific community worldwide, join us in Boston to hear how they address the major challenges facing the industry.
This conference will:
• Explore the current state of play and future of next generation RNA therapeutics
• Discover next generation RNA therapeutics and vaccine modalities
• Optimize the latest advancements of next generation RNA formulation and delivery strategies
• Tune into how companies are innovating immunotherapy approaches through next generation RNA therapeutics
• Combat toxicology, pharmacology and scalability challenges of next generation RNA therapeutics
Tickets https://go.evvnt.com/996084-2?pid=5248
Brochure https://go.evvnt.com/996084-3?pid=5248
Speakers: Andreas Kuhn Senior Vice President - RNA Biochemistry & Manufacturing BioNTech, John Androsavich Global Head - RNA Medicine Lead Pfizer, Susan Goody Director & Head of Toxicology Moderna Therapeutics, Nathaniel Wang Chief Executive Officer & Co-Founder Replicate Bioscience, Alex Wesselhoeft Founder & Director of Molecular Biology Orna Therapeutics, Tasuku Kitada President, Director, Co-founder, Head of Research & Development Strand Therapeutics Inc., Yusuf Erkul Co-founder & Chief Executive Officer Kernal Biologics Inc., Philip Santangelo Professor Emory University School Of Medicine, Gopi Shanker Chief Scientific Officer Tevard Bioscience, Mathieu Ghadanfar Chief Medical Officer & Research & Development Director Ziphius Vaccines, Mat Falkowski Chief Executive Officer CEO Circularis Biotechnologies Inc., Robert Kruse Clinical Fellow Harvard College, Thomas Colace Assistant Director, LNP Formulation Kernal Biologics Inc., Gillis Otten Head of Immunology Research Seqirus Inc., Allen Horhota Senior Director & Head of Delivery Orna Therapeutics, Anna Blakney Assistant Professor University of British Columbia, Andrew Geall Co-founder & Chief Development Officer Replicate Bioscience, Ethan Settembre Vice President, Head of Research Seqirus Inc., Velia Siciliano Principal Investigator - Synthetic & System Biology for Biomedicine Italian Institute of Technology, Andy Berglund Director - Ribonucleic Acid Institute & Professor - Biological Sciences University at Albany
